Amgen's Dividend Track Record in Bear Markets Draws Defensive Demand as Fed Hike Cycle Pressures S&P 500

The Quick Take

• Amgen's bear market outperformance record draws defensive positioning demand as Fed hike cycle pressures equities
• Biologics franchise recurring revenue and dividend growth history provide earnings floor in risk-off environments
• Biosimilars expansion adds medium-term growth to pure defensive profile, broadening institutional appeal

The case for Amgen as a defensive holding rests on structural characteristics that have historically decoupled its earnings trajectory from broader market cycles. As a leading manufacturer of biologic medicines — including Enbrel, Otezla, and Repatha for chronic conditions requiring long-term treatment — Amgen's revenue base is driven by patient adherence rather than discretionary consumer or business spending cycles. This creates earnings predictability that makes the stock behave differently from cyclical market components during downturns, and that predictability has translated into consistent outperformance relative to the S&P 500 in prior bear markets.

The pharmaceutical giant's dividend history reinforces this defensive profile. Amgen has maintained and grown its quarterly dividend through multiple market cycles, including the 2008 financial crisis, the 2020 pandemic shock, and the 2022 rate-driven equity selloff. The current forward yield represents a compelling risk-adjusted income stream relative to the volatility of more cyclical dividend payers. Value investors and income-focused institutional allocators have historically rotated into Amgen when rate uncertainty threatens growth equity valuations, creating a self-reinforcing flow dynamic during stress periods.

The current environment — Fed tightening, elevated rate uncertainty, and compressed growth equity multiples — mirrors prior periods when Amgen's relative outperformance has been most pronounced. The company's ongoing biosimilars expansion programme adds a medium-term growth vector that reduces the value trap risk typically associated with pure defensive allocations, making it more attractive to balanced portfolios than pure utility or consumer staples plays. The combination of defensive resilience and biosimilar growth optionality positions Amgen as a holding that can perform across a range of macro scenarios in the current cycle.

Synthesized from 2 sources.